Orig3N Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orig3N Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10984
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orig3N Inc (Orig3N), a biotechnology company that focuses on the research, development and treatment of genetically inherited diseases. The company offers DNA test kits which include SUPERHERO for analyzing strength, intelligence and speed; FITNESS that provides reports and analysis on various aspects of fitness including exercise recovery, metabolism, muscle strength, endurance, joints and power performance; Beauty for assessment on key aspects of skin including hydration, aging, elasticity, UV sensitivity. It also provides Life Capsule, a blood cell repository for regenerative medicine development. The company uses its regenerative medicine technology to develop ORIG3N C3LL Cardiomyocytes for diagnosing and treating diseases. Orig3N is headquartered in Boston, Massachusetts, the US.

Orig3N Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orig3N Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Orig3N Inc, Medical Devices Deals, 2012 to YTD 2018 9
Orig3N Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orig3N Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Orig3n Raises Funds through Initial Closing of Series B Financing 12
Orig3n Raises USD20 Million in Venture Financing 14
Orig3N Raises USD12.5 Million in Series A Financing 16
Orig3N Raises USD5 Million in Venture Financing 18
Orig3N Raises Funds through Venture Financing 19
Orig3N Raises USD3.1 Million in Venture Financing 20
Partnerships 22
Orig3n Enters into Research Agreement with Harvard University 22
ORIG3N Partners with Kangstem Biotech 23
Orig3N Enters into Agreement with Sharp Edge Labs 24
Orig3N Enters into Research Agreement with Sturge-Weber 25
Orig3N Inc – Key Competitors 26
Orig3N Inc – Key Employees 27
Orig3N Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Other Significant Developments 29
Jun 08, 2018: Orig3n Announces Osteoarthritis Cartilage Regeneration for First Cell Therapy Program 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Orig3N Inc, Pharmaceuticals & Healthcare, Key Facts 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orig3N Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orig3N Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Orig3N Inc, Medical Devices Deals, 2012 to YTD 2018 9
Orig3N Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orig3n Raises Funds through Initial Closing of Series B Financing 12
Orig3n Raises USD20 Million in Venture Financing 14
Orig3N Raises USD12.5 Million in Series A Financing 16
Orig3N Raises USD5 Million in Venture Financing 18
Orig3N Raises Funds through Venture Financing 19
Orig3N Raises USD3.1 Million in Venture Financing 20
Orig3n Enters into Research Agreement with Harvard University 22
ORIG3N Partners with Kangstem Biotech 23
Orig3N Enters into Agreement with Sharp Edge Labs 24
Orig3N Enters into Research Agreement with Sturge-Weber 25
Orig3N Inc, Key Competitors 26
Orig3N Inc, Key Employees 27

List of Figures
Orig3N Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orig3N Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Orig3N Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Orig3N Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bawag Psk:企業の戦略・SWOT・財務分析
    Bawag Psk - Strategy, SWOT and Corporate Finance Report Summary Bawag Psk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Promimic AB-医療機器分野:企業M&A・提携分析
    Summary Promimic AB (Promimic) is a biomaterial company that develops and markets implant surface modifications and synthetic bones. The company’s products comprise metals, ceramics, polymers, porous materials and pyrocarbon. Its HA-nano surface is a coating based on nanocrystalline hydroxyapatite p …
  • Mace Group Ltd:企業の戦略・SWOT・財務情報
    Mace Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Mace Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Taisei Lamick Co., Ltd.:企業の戦略・SWOT・財務情報
    Taisei Lamick Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taisei Lamick Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Pernod Ricard SA (RI):企業の財務・戦略的SWOT分析
    Pernod Ricard SA (RI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Marina Portoroz d.d.:企業の戦略・SWOT・財務情報
    Marina Portoroz d.d. - Strategy, SWOT and Corporate Finance Report Summary Marina Portoroz d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • West Cornwall Pasty Co. Ltd:企業の戦略・SWOT・財務分析
    West Cornwall Pasty Co. Ltd - Strategy, SWOT and Corporate Finance Report Summary West Cornwall Pasty Co. Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Parkland Fuel Corporation (PKI):石油・ガス:M&Aディール及び事業提携情報
    Summary Parkland Fuel Corp (Parkland) is a downstream energy company. It markets various fuel and petroleum products, including gasoline, propane, lubricants, diesel, heating oil, and other petroleum products. The company maintains a portfolio of supply relationships, storage infrastructure, and thi …
  • Acer Therapeutics Inc (ACER):医療機器:M&Aディール及び事業提携情報
    Summary Acer Therapeutics Inc (Acer), formerly Opexa Therapeutics Inc is a pharmaceutical company that offers acquisition, development and commercialization of therapies for patients with serious rare diseases. The company offers treatment of autoimmune disorders, rheumatoid arthritis, diabetes and …
  • Payton Planar Magnetics Ltd (PAY):企業の財務・戦略的SWOT分析
    Payton Planar Magnetics Ltd (PAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • MedImmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respi …
  • Codan Radio Communications:企業の戦略・SWOT・財務情報
    Codan Radio Communications - Strategy, SWOT and Corporate Finance Report Summary Codan Radio Communications - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Enercon Services Inc:電力:M&Aディール及び事業提携情報
    Summary Enercon Services, Inc. (Enercon) is a diversified consulting company offering architectural engineering, environmental, technical and management services. Its offerings include licensing, operations, permitting, construction, decommissioning, and staff augmentation, cyber security and regula …
  • United International Enterprises Limited:企業の戦略・SWOT・財務情報
    United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Total E&P USA Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Total E&P USA Inc (TEP USA) formerly Elf Exploration Inc, a subsidiary of Total S.A., is an energy service providing company that explores and produces crude oil and natural gas. The company offers offshore oil production and exploration in the Gulf of Mexico to onshore unconventional shale …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Beiersdorf AG:企業の戦略・SWOT・財務情報
    Beiersdorf AG - Strategy, SWOT and Corporate Finance Report Summary Beiersdorf AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • FTI Consulting Inc (FCN):企業の財務・戦略的SWOT分析
    Summary FTI Consulting Inc (FTI) is an independent global consulting service provider. The company offers corporate finance and restructuring, consulting, strategic communications, economic consulting, forensic and litigation, technology and specialty services. It provides it services across various …
  • Sopharma AD (3JR):企業の財務・戦略的SWOT分析
    Sopharma AD (3JR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Indianapolis Power & Light Co-エネルギー分野:企業M&A・提携分析
    Summary Indianapolis Power & Light Co (IPL), a subsidiary of IPALCO Enterprises Inc, is an integrated electric utility. The company generates, transmits, distributes, and sells electric energy. It produces electricity from coal, oil, and natural gas sources. IPL owns and operates power plants in Ind …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆